StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $150.00 | $152.25 | +1.50% | 1.4M |
| 05-11 | $152.00 | $150.59 | -0.93% | 1.2M |
| 05-12 | $151.43 | $155.80 | +2.89% | 1.3M |
| 05-13 | $157.95 | $161.32 | +2.13% | 1.6M |
| 05-14 | $161.63 | $161.02 | -0.37% | 0.4M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Each factor shows NBIX's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-07-28 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $879.14M | $814.50M | $2.86B | $2.06B | $1.26B |
Operating Income | Not available | $193.40M | $619.10M | $408.20M | $169.20M |
Net Income | Not available | $197.90M | $478.60M | $324.90M | $115.40M |
EPS (Diluted) | $1.65 | $1.91 | $4.67 | $3.19 | $1.13 |
Total Assets | Not available | $4.91B | $4.63B | $4.27B | $3.89B |
Total Liabilities | Not available | $1.50B | $1.38B | $1.26B | $1.20B |
Cash & Equivalents | Not available | $266.50M | $713.00M | $340.20M | $264.00M |
Free Cash Flow OCF − CapEx | Not available | $136.70M | $748.70M | $357.90M | $143.60M |
Shares Outstanding | Not available | 100.60M | 100.10M | 99.70M | 99.00M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Each row shows where NBIX sits in our scored universe today on a single observational measurement. P85 means NBIX ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
What drives NBIX's price movement
Follow the money. Institutional flows and fund positioning are key drivers.
Mixed retail/institutional activity
Moderate news sensitivity
Moderate sentiment influence
Moderate volume-sensitivity
Underperforming peers — laggard in sector
Not momentum-driven — mean-reverts quickly
DNA analysis is based on current factor scoring. Not investment advice.
Quiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.